Nuvalent Inc Ordinary Shares - Class A NUVL 深 沪
等待开盘 09-09 09:30:00 美东时间
79.83
-1.060
-1.31%
华盛通- 最 高81.61
- 今 开80.77
- 成交量 45.31万股
- 最 低 74.40
- 昨 收 80.89
- 总市值 57.56亿
- 52周最高 113.51
- 市盈率 静 --
- 换手率 0.63%
- 52周最低 55.535
- 委 比 -0.70%
- 总股本 7210.48万
- 历史最高 113.51
- 量 比 0.82
- 振 幅 8.91%
- 历史最低 7.09
- 每 手 1
- 风险率 10.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅403.28%！瑞杰金融首予Kalaris Therapeutics"强烈买入"评级，目标价23美元
今日重点评级关注：花旗：维持Ionis Pharmaceuticals"买入"评级，目标价从69美元升至84美元；Melius Research：上调康明斯评级至"买入"，目标价500美元
09-04 09:49
Raymond James Initiates Coverage On Nuvalent with Outperform Rating, Announces Price Target of $105
Raymond James analyst Chris Raymond initiates coverage on Nuvalent (NASDAQ:NUVL) with a Outperform rating and announces Price Target of $105.
09-04 00:51
Piper Sandler initiates coverage of oncology companies
Piper Sandler launched coverage for a few biotech companies in the oncology space, as mentioned below: CG Oncology (NASDAQ:CGON) rated Overweight with a $55 price target: "Investor expectations for cr...
08-19 23:17
Piper Sandler Initiates Coverage On Nuvalent with Overweight Rating, Announces Price Target of $112
Piper Sandler analyst Kelsey Goodwin initiates coverage on Nuvalent (NASDAQ:NUVL) with a Overweight rating and announces Price Target of $112.
08-19 19:50
Nuvalent shares are trading lower after the company reported worse-than-expected Q2 financial results.
Nuvalent shares are trading lower after the company reported worse-than-expecte...
08-08 00:32
Nuvalent Q2 EPS $(1.39) Misses $(1.22) Estimate
Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.22) by 13.65 percent. This is a 57.95 percent decrease over losses of $(0.88) per share from the
08-07 18:40
Nuvalent Initiates Phase 3 ALKAZAR Clinical Trial
Nuvalent ( ($NUVL) ) has issued an update. On July 21, 2025, Nuvalent, Inc. ann...
07-21 18:58
美股大行评级 | 潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级；联邦快递遭多家机构下调目标价>>
06-26 08:38
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
HC Wainwright & Co. Maintains Buy on Nuvalent, Raises Price Target to $130
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Nuvalent (NASDAQ:NUVL) with a Buy and raises the price target from $110 to $130.
06-24 23:03
